quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Coca-Cola (KO) Ascends While Market Falls: Some Facts to Note

View original at finance.yahoo.com
Coca-Cola (KO) Ascends While Market Falls: Some Facts to Note Coca-Cola (KO) closed the most recent trading day at $75.71, moving +1.37% from the previous trading session…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Changes in estimates have a direct relationship with upcoming stock price performance

    60% confidence

  • Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.31% increase

    60% confidence

  • For the entire fiscal year, revenue is predicted at $49.45 billion, indicating a change of +3.24% from the former year

    60% confidence

  • For the entire fiscal year, earnings are predicted at $3.24 per share, indicating a change of +8% from the former year

    60% confidence

  • Coca-Cola's revenue is estimated at $12.32 billion, up 10.73% from the prior-year quarter

    60% confidence

  • Coca-Cola is predicted to post an EPS of $0.81, indicating a 10.96% growth compared to the equivalent quarter last year

    60% confidence

  • Recent revisions to analyst estimates tend to reflect the evolving nature of short-term business trends, with upbeat changes indicating analysts' favorable outlook

    60% confidence

  • The Zacks Rank system has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Coca-Cola (KO) Ascends While Market Falls: Some Facts to Note — Source | Via News | pt.VIA.NEWS